VBL Theraputics

Since 2000 / Life Sciences

    CEO

    Prof. Dror Harats MD

    NEWS

    VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis

    Read More >

    VBL Therapeutics Announces Removal of FDA Partial Clinical Hold on VB-111

    Read More >

     Ltd. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics' clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body's natural physiologic and genetic regulatory elements.

    VBL’s oncology program is based on the Company’s proprietary Vascular Targeting System™ or VTS platform technology which utilizes genetically targeted therapy to destroy newly formed blood vessels. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma. VB-111 has received orphan drug designation in both the US and Europe and was granted Fast Track designation by the FDA. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in the first half of 2015, under an SPA granted by the FDA.

    VBL’s anti-inflammatory program is based on the Lecinoxoids platform technology. Lecinoxoids are a novel class of small molecules developed by VBL that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. VB-201, the lead product candidate from VBL’s anti-inflammatory program, is a proprietary, first-in-class, specific innate immunity disease-modifying medicine in development for the effective treatment of chronic immune-inflammatory diseases. VB-201 has completed Phase 2 clinical trials for psoriasis and ulcerative colitis, with top-line results expected in the first quarter of 2015.

    Both compounds target markets with unmet need for safe and well-tolerated treatments, and provide differentiation from current or proposed treatments. We believe our two distinct platform technologies provide us with an opportunity to develop a diversified portfolio of product candidates targeting both orphan indications and large markets.

     

    秒速赛车【gd1133.com光大彩票】-新闻 秒速赛车【gd1100.com光大彩票】-法治 秒速赛车【gd1144.com光大彩票】-案件 秒速赛车【gd1155.com光大彩票】-检察 秒速赛车【gd1166.com光大彩票】-理论 秒速赛车【gd1177.com光大彩票】-新媒体 秒速赛车【gd9900.com光大彩票】-视频 秒速赛车【gd9911.com光大彩票】-评论 秒速赛车【gd9922.com光大彩票】-文化 秒速赛车【gd9933.com光大彩票】-人物 秒速赛车【gd9944.com光大彩票】-舆情 秒速赛车【gd9955.com光大彩票】-装备 放课后的秘密画室 秒速赛车【gd9977.com光大彩票】-今日推荐 秒速赛车【gd1133.com光大彩票】-图片聚焦 秒速赛车【gd1100.com光大彩票】-以案说法 秒速赛车【gd1144.com光大彩票】-检察视界 秒速赛车【gd1155.com光大彩票】-城东区 秒速赛车【gd1166.com光大彩票】-城中区 秒速赛车【gd1177.com光大彩票】-城西区 秒速赛车【gd9900.com光大彩票】-城北区 秒速赛车【gd9911.com光大彩票】-大通县 秒速赛车【gd9922.com光大彩票】-湟中县 秒速赛车【gd9933.com光大彩票】-湟源县 秒速赛车【gd9944.com光大彩票】-经济技术开发区 秒速赛车【gd9955.com光大彩票】-城南新区 秒速赛车【gd9977.com光大彩票】-高新技术开发区 秒速赛车【gd1133.com光大彩票】-海湖新区 秒速赛车【gd1100.com光大彩票】-放课后的秘密画室 秒速赛车【gd1144.com光大彩票】-滚动 秒速赛车【gd1155.com光大彩票】-国内 秒速赛车【gd1166.com光大彩票】-国际 秒速赛车【gd1177.com光大彩票】-军事 秒速赛车【gd9900.com光大彩票】-社会 秒速赛车【gd9911.com光大彩票】-财经 秒速赛车【gd9922.com光大彩票】-产经 秒速赛车【gd9933.com光大彩票】-房产 秒速赛车【gd9944.com光大彩票】-金融 秒速赛车【gd9955.com光大彩票】-证券 秒速赛车【gd9977.com光大彩票】-汽车 秒速赛车【gd1133.com光大彩票】-IT 秒速赛车【gd1100.com光大彩票】-能源 秒速赛车【gd1144.com光大彩票】-港澳 秒速赛车【gd1155.com光大彩票】-台湾 秒速赛车【gd1166.com光大彩票】-华人 秒速赛车【gd1177.com光大彩票】-侨网 秒速赛车【gd9900.com光大彩票】-经纬 秒速赛车【gd9911.com光大彩票】-English 秒速赛车【gd9922.com光大彩票】-图片 秒速赛车【gd9933.com光大彩票】-视频 秒速赛车【gd9944.com光大彩票】-直播 北京PK10【gd9955.com光大彩票】-娱乐 PK10开奖【gd9977.com光大彩票】-体育 pk10平台【gd1133.com光大彩票】-文化 Pk10计划【gd1100.com光大彩票】-健康 pk10网址【gd1144.com光大彩票】-生活 pk10开户【gd1155.com光大彩票】-葡萄酒 pk10赛车【gd1166.com光大彩票】-微视界 PK10投注平台【gd1177.com光大彩票】-演出 PK10注册【gd9900.com光大彩票】-专题 PK10开户【gd9911.com光大彩票】-理论 北京PK10【gd9922.com光大彩票】-新媒体 PK10开奖【gd9933.com光大彩票】-供稿 pk10平台【gd9944.com光大彩票】-新闻 Pk10计划【gd9955.com光大彩票】-时事 pk10网址【gd9977.com光大彩票】-视频 pk10开户【gd1133.com光大彩票】-评论 pk10赛车【gd1100.com光大彩票】-股票 PK10投注平台【gd1144.com光大彩票】-区块链 PK10注册【gd1155.com光大彩票】-港股 PK10开户【gd1166.com光大彩票】-科创 北京PK10【gd1177.com光大彩票】-基金 PK10开奖【gd9900.com光大彩票】-私募 pk10平台【gd9911.com光大彩票】-理财 Pk10计划【gd9922.com光大彩票】-信托 pk10网址【gd9933.com光大彩票】-P2P pk10开户【gd9944.com光大彩票】-科技 pk10赛车【gd9955.com光大彩票】-债券 PK10投注平台【gd9977.com光大彩票】-互金 PK10注册【gd1133.com光大彩票】-期货 PK10开户【gd1100.com光大彩票】-原油 北京PK10【gd1144.com光大彩票】-大宗 PK10开奖【gd1155.com光大彩票】-期指 pk10平台【gd1166.com光大彩票】-保险 Pk10计划【gd1177.com光大彩票】-银行 pk10网址【gd9900.com光大彩票】-黄金 pk10开户【gd9911.com光大彩票】-外汇 pk10赛车【gd9922.com光大彩票】-行情 PK10投注平台【gd9933.com光大彩票】-数据 PK10注册【gd9944.com光大彩票】-房产 PK10开户【gd9955.com光大彩票】-汽车 北京PK10【gd9977.com光大彩票】-博客 PK10开奖【gd1133.com光大彩票】-农金 pk10平台【gd1100.com光大彩票】-名家 Pk10计划【gd1144.com光大彩票】-消金 pk10网址【gd1155.com光大彩票】-美股 pk10开户【gd1166.com光大彩票】-创投 pk10赛车【gd1177.com光大彩票】-游戏 PK10投注平台【gd9900.com光大彩票】-滚动 PK10注册【gd9911.com光大彩票】-新浪 PK10开户【gd9922.com光大彩票】-正义网